1Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis [J]. Mol Aspects Med, 2010,31(2) :205-214.
2Christofori G. New signals from the invasive front [J]. Nature, 2006,441 (7092) : 444-450.
3Hanna E, Quick J, Libutti S K. The : a novel target for cancer therapy [J]. Oral Dis, 2009,15(1) :8-17.
4Senetar M A, Moncman C L, McCann R O. Talin2 is induced during striated muscle differentiation and is targeted to stable adhesion complexes in mature muscle [J]. Cell Motil Cytoskeleton, 2007,64(3) : 157-173.
5Petrich B G, Marchese P, Ruggefi Z M, et al. Talin is required for integrin- mediated platelet function in hemostasis and thrombosis [J]. J Exp Med, 2007, 204(13) :3103-3111.
6Nieswandt B, Moser M, Pleines I, et al. Loss of talinl in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo [J]. J Esp Med, 2007,204(13):3113-3118.
7Sakamoto S, McCann R O, Dhir R, et al. Talinl promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance [J]. Cancer Res, 2010,70(5) : 1885-1895.
8Wang P, Ballestrem C, Streuli C H. The C terminus of talin links integrins to cell cycle progression [J]. J Cell Biol, 2011,195(3) :499-513.
9Simonson W T, Franco S J, Huttenlocher A. Talinl regulates TCR- mediated LFA-1 function [J]. J Immunol, 2006,177(11) :7707-7714.
10Weruimont S A, Wiemer A J, Bennin D A, et al. Contact-dependent T cell activation and T ceil stopping require talinl [J]. J Immunol, 2011,187(12): 6256-6267.
